HK1202862A1 - 喹啉基吡咯並嘧啶基稠環化合物或其鹽 - Google Patents

喹啉基吡咯並嘧啶基稠環化合物或其鹽

Info

Publication number
HK1202862A1
HK1202862A1 HK15103353.8A HK15103353A HK1202862A1 HK 1202862 A1 HK1202862 A1 HK 1202862A1 HK 15103353 A HK15103353 A HK 15103353A HK 1202862 A1 HK1202862 A1 HK 1202862A1
Authority
HK
Hong Kong
Prior art keywords
quinolylpyrrolopyrimidyl
fused
salt
ring compound
compound
Prior art date
Application number
HK15103353.8A
Other languages
English (en)
Inventor
相良武
伊藤智
大槻幸惠
野野下克昌
Original Assignee
大鵬藥品工業株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大鵬藥品工業株式會社 filed Critical 大鵬藥品工業株式會社
Publication of HK1202862A1 publication Critical patent/HK1202862A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK15103353.8A 2012-02-23 2015-04-02 喹啉基吡咯並嘧啶基稠環化合物或其鹽 HK1202862A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012037565 2012-02-23
PCT/JP2013/054615 WO2013125709A1 (ja) 2012-02-23 2013-02-22 キノリルピロロピリミジル縮合環化合物又はその塩

Publications (1)

Publication Number Publication Date
HK1202862A1 true HK1202862A1 (zh) 2015-10-09

Family

ID=49005885

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103353.8A HK1202862A1 (zh) 2012-02-23 2015-04-02 喹啉基吡咯並嘧啶基稠環化合物或其鹽

Country Status (16)

Country Link
US (1) US8889666B2 (zh)
EP (1) EP2722332B1 (zh)
JP (1) JP5557963B2 (zh)
KR (1) KR101660145B1 (zh)
CN (1) CN104136438B (zh)
CA (1) CA2861980C (zh)
DK (1) DK2722332T3 (zh)
ES (1) ES2580530T3 (zh)
HK (1) HK1202862A1 (zh)
HU (1) HUE029343T2 (zh)
MX (1) MX351863B (zh)
PL (1) PL2722332T3 (zh)
RU (1) RU2581039C1 (zh)
SG (1) SG11201402876UA (zh)
TW (1) TWI496783B (zh)
WO (1) WO2013125709A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2898274A1 (en) * 2013-02-22 2014-08-28 Taiho Pharmaceutical Co., Ltd. Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method
EP3037424B1 (en) * 2013-08-22 2017-11-08 Taiho Pharmaceutical Co., Ltd. Novel quinoline-substituted compound
MY196077A (en) * 2015-03-31 2023-03-13 Taiho Pharmaceutical Co Ltd Crystal Of 3,5-Disubstituted Benzene Alkynyl Compound
WO2017064558A1 (ja) * 2015-10-14 2017-04-20 大鵬薬品工業株式会社 新規免疫賦活化剤
JOP20190073A1 (ar) * 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
WO2019045036A1 (ja) 2017-09-01 2019-03-07 大鵬薬品工業株式会社 エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤
WO2021057796A1 (zh) * 2019-09-29 2021-04-01 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
CN115785107A (zh) * 2022-12-15 2023-03-14 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2601766A1 (en) * 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
WO2007075554A2 (en) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
CA2647391C (en) * 2006-04-04 2015-12-29 The Regents Of The University Of California Kinase antagonists
EP2051982A1 (en) * 2006-08-10 2009-04-29 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
CN102887900B (zh) * 2006-09-22 2015-04-29 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CN102146059A (zh) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 喹唑啉衍生物、制备方法及其应用
SG186378A1 (en) * 2010-06-23 2013-01-30 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
MX2013004894A (es) * 2010-11-01 2013-10-17 Celgene Avilomics Res Inc Compuestos heterociclicos y usos de los mismos.

Also Published As

Publication number Publication date
EP2722332A4 (en) 2014-04-23
EP2722332B1 (en) 2016-04-20
KR101660145B1 (ko) 2016-09-26
CN104136438B (zh) 2016-04-06
CN104136438A (zh) 2014-11-05
US8889666B2 (en) 2014-11-18
JP5557963B2 (ja) 2014-07-23
KR20140117647A (ko) 2014-10-07
MX351863B (es) 2017-10-30
US20140057899A1 (en) 2014-02-27
CA2861980A1 (en) 2013-08-29
JPWO2013125709A1 (ja) 2015-07-30
MX2014009991A (es) 2014-09-08
EP2722332A1 (en) 2014-04-23
CA2861980C (en) 2016-11-08
HUE029343T2 (en) 2017-02-28
TWI496783B (zh) 2015-08-21
AU2013223052A1 (en) 2014-07-03
DK2722332T3 (en) 2016-06-20
WO2013125709A1 (ja) 2013-08-29
RU2581039C1 (ru) 2016-04-10
ES2580530T3 (es) 2016-08-24
SG11201402876UA (en) 2014-12-30
PL2722332T3 (pl) 2016-10-31
TW201339160A (zh) 2013-10-01

Similar Documents

Publication Publication Date Title
IL273276A (en) salt crystals
EP2842955A4 (en) TRK-INHIBITING CONNECTION
HK1188451A1 (zh) 咪唑並噁嗪化合物或其鹽
AP2014007810A0 (en) Imidazopyrrolidinone compounds
EP2925129A4 (en) PRO-NEUROGENIC COMPOUNDS
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2887803A4 (en) PRO-NEUROGENIC COMPOUNDS
HK1202862A1 (zh) 喹啉基吡咯並嘧啶基稠環化合物或其鹽
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
HK1199730A1 (zh) 哌啶化合物或其鹽
GB201220843D0 (en) Compound
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
HK1185079A1 (zh) 新型二環式化合物或其鹽
GB201209096D0 (en) Compounds
HK1215571A1 (zh) 二鹽酸科比思特
GB201216309D0 (en) Compound
GB201215675D0 (en) Compound
GB201217310D0 (en) Compounds
GB201216448D0 (en) Compound
AU2013223052B2 (en) Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof
GB201222716D0 (en) Compound
GB201218758D0 (en) Compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210221